Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

Published on Feb 1, 2021in European Journal of Radiology2.687
· DOI :10.1016/J.EJRAD.2020.109484
Jordi Rimola43
Estimated H-index: 43
,
Leonardo Gomes da Fonseca7
Estimated H-index: 7
+ 16 AuthorsMaria Reig33
Estimated H-index: 33
Sources
Abstract
Abstract Background and Aims Immune-checkpoint inhibitors are effective in many advanced tumors. However, there is scarce information regarding the radiological response to these agents in hepatocellular carcinoma outside clinical trials. We aimed to describe the radiological response in a retrospective cohort of hepatocellular carcinoma patients treated with nivolumab and to analyze the radiological evolution according to tumor response at first posttreatment radiological assessment. Methods We reviewed pretreatment and posttreatment images (CT or MRI) obtained at different timepoints in patients with hepatocellular carcinoma treated with nivolumab outside clinical trials at seven Spanish centers, assessing the response according to RECIST 1.1 and iRECIST and registering atypical responses. We also analyzed the imaging findings on subsequent assessments according to tumor status on the first posttreatment imaging assessment. Results From the 118 patients with hepatocellular carcinoma treated with nivolumab, we finally analyzed data from 31 patients (71% Child-Pugh A; 74% BCLC-C). Median follow-up was 8.39 months [IQR 5.00-10.92]; median overall survival was 12.82 months (95%CI 10.92-34.79). According to RECIST 1.1, the objective response rate was 16% and according to iRECIST, the objective response rate was 22.6%. Findings at the first posttreatment assessment varied, showing stable disease in 44.8% of patients; findings during follow-up also varied widely, including 4 hyperprogressions and 3 pseudoprogressions. Conclusion Imaging findings during nivolumab treatment are heterogeneous between and within patients. Progression of disease does not always signify treatment failure, and surrogate endpoints may not reflect survival outcomes, making the management of hepatocellular carcinoma patients under immunotherapy challenging.
📖 Papers frequently viewed together
1 Citations
21 Citations
5 Citations
References25
Newest
#1Katherine A. Donovan (Harvard University)H-Index: 17
#2Fleur M. Ferguson (Harvard University)H-Index: 11
Last. Eric S. Fischer (Harvard University)H-Index: 29
view all 34 authors...
Summary Targeted protein degradation (TPD) refers to the use of small molecules to induce ubiquitin-dependent degradation of proteins. TPD is of interest in drug development, as it can address previously inaccessible targets. However, degrader discovery and optimization remains an inefficient process due to a lack of understanding of the relative importance of the key molecular events required to induce target degradation. Here, we use chemo-proteomics to annotate the degradable kinome. Our expa...
63 CitationsSource
#1Ankur Sharma (Genome Institute of Singapore)H-Index: 12
#2Justine Jia Wen Seow (Genome Institute of Singapore)H-Index: 3
Last. Ramanuj DasGupta (Genome Institute of Singapore)H-Index: 29
view all 24 authors...
Summary We employed scRNA sequencing to extensively characterize the cellular landscape of human liver from development to disease. Analysis of ∼212,000 cells representing human fetal, hepatocellular carcinoma (HCC), and mouse liver revealed remarkable fetal-like reprogramming of the tumor microenvironment. Specifically, the HCC ecosystem displayed features reminiscent of fetal development, including re-emergence of fetal-associated endothelial cells (PLVAP/VEGFR2) and fetal-like (FOLR2) tumor-a...
27 CitationsSource
Abstract Background The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinom...
761 CitationsSource
#1Jordi Rimola (University of Barcelona)H-Index: 43
Tumor heterogeneity in hepatocellular carcinomas (HCC) occurs at different levels. On conventional imaging modalities, the spectrum of tumor heterogeneity is evident in the dynamic enhancement pattern, where the characteristic wash-in and wash-out is present in only 60% of small HCCs. In larger HCCs, heterogeneity within the tumor, known as the mosaic pattern, can reflect the presence of different grades of HCC differentiation. The advent of functional imaging techniques has not improved the dia...
6 CitationsSource
#1Richard S. Finn (UCLA: University of California, Los Angeles)H-Index: 80
#2Baek-Yeol Ryoo (UOU: University of Ulsan)H-Index: 34
Last. Ann-Lii Cheng (NTU: National Taiwan University)H-Index: 90
view all 20 authors...
PURPOSEPembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated ...
328 CitationsSource
#1Juan C. Osorio (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
#2Kathryn C. Arbour (Cornell University)H-Index: 18
Last. Matthew D. Hellmann (Cornell University)H-Index: 77
view all 17 authors...
PURPOSEResponse to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity ...
29 CitationsSource
#1T. Yau (HKU: University of Hong Kong)H-Index: 5
#1Thomas Yau (HKU: University of Hong Kong)H-Index: 43
Last. Bruno Sangro (University of Navarra)H-Index: 77
view all 20 authors...
Abstract Background SOR is approved as 1L therapy for pts with aHCC, but there is still an unmet need to prolong survival and improve tolerability. This phase III study compared clinical efficacy and safety of NIVO with SOR as 1L therapy in pts with aHCC. Methods Systemic therapy–naive pts aged ≥18 years with aHCC were randomized 1:1 to NIVO (240mg IV Q2W) or SOR (400mg oral BID). Primary endpoint was overall survival (OS). Additional endpoints were objective response rate (ORR) and progression-...
237 CitationsSource
#1Jordi Bruix (University of Barcelona)H-Index: 115
#2Leonardo G. Da Fonseca (University of Barcelona)H-Index: 5
Last. Maria Reig (University of Barcelona)H-Index: 33
view all 3 authors...
Systemic treatment for hepatocellular carcinoma (HCC) has been boosted by the incorporation of new agents after many negative phase III trials in the decade since the approval of sorafenib. Sorafenib introduced the concept that targeting specific hallmarks of hepatocarcinogenesis could modify the dismal prognosis of this disease, with the drug remaining a cornerstone in the upfront therapy for advanced HCC. The design of clinical trials in this malignancy is complicated by important obstacles re...
63 CitationsSource
#1Thomas YauH-Index: 43
#2Yoon-Koo Kang (Asan Medical Center)H-Index: 24
Last. Chiun Hsu (NTU: National Taiwan University)H-Index: 44
view all 20 authors...
4012Background: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% a...
112 CitationsSource
#1Edith Borcoman (Curie Institute)H-Index: 9
#2Yada KanjanapanH-Index: 9
Last. C. Le Tourneau (Curie Institute)H-Index: 20
view all 9 authors...
ABSTRACT Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough with immunotherapy is its potential to achieve durable responses in a subset of patients with advanced cancer that can be maintained several years even after stopping the treatment. No standardized definition of durable response exists in the literature, and the optimal duration of treatment in case of du...
133 CitationsSource
Cited By4
Newest
#2Gemma IserteH-Index: 1
Last. Maria Reig (University of Barcelona)H-Index: 33
view all 0 authors...
Abstract null null The landscape of hepatocellular carcinoma (HCC) has changed since the incorporation of sorafenib in 2007 as the first pharmacological treatment for HCC. The combination of atezolizumab plus bevacizumab is currently the first-line treatment for HCC patients, and there are several second-line options approved for patients who had received sorafenib as the first-line treatment. The advantage of having multiple options of pharmacological treatment for HCC patients is associated to...
Source
#1Jordi Bruix (University of Barcelona)H-Index: 115
#2Stephen L. Chan (CUHK: The Chinese University of Hong Kong)H-Index: 55
Last. Bruno Sangro (University of Navarra)H-Index: 77
view all 5 authors...
The last 5 years have witnessed relevant advances in the systemic treatment of hepatocellular carcinoma. New data have emerged since the development of the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma in 2018. Drugs licensed in some countries now include 4 oral multi-tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), 1 anti-angiogenic antibody (ramucirumab) and 4 immune checkpoint inhibitors, alone or in combination (atezolizumab ...
3 CitationsSource
#1Antonio D'Alessio (Humanitas University)H-Index: 1
#2Antonella Cammarota (Humanitas University)H-Index: 1
Last. Lorenza Rimassa (Humanitas University)H-Index: 32
view all 6 authors...
INTRODUCTION The treatment of unresectable hepatocellular carcinoma (HCC) has radically changed after the approval of the combination of atezolizumab plus bevacizumab as first-line treatment. A strong preclinical rationale exists to support the combination of bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (mAb), and atezolizumab, an anti-programmed death ligand 1 mAb. The efficacy of the combination was first assessed in the phase Ib GO30140 study, and the combinatio...
Source
#1Bruno Sangro (University of Navarra)H-Index: 77
#2Pablo Sarobe (University of Navarra)H-Index: 38
Last. Ignacio Melero (University of Navarra)H-Index: 81
view all 4 authors...
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy with checkpoint inhibitors has shown strong anti-tumour activity in a subset of patients and the combination of the anti-PDL1 antibody atezolizumab and the VEGF-neutralizing antibody bevacizumab has or will soon become the standard of care as ...
7 CitationsSource
#1Jordi Bruix (University of Barcelona)H-Index: 115
Design and execution of clinical trials use definitions and criteria to permit a homogeneous study development avoiding heterogeneous decisions by investigators at different sites. Ideally, definitions and decision making in clinical practice should mimic those implemented in trials, but this is not the case. Target population is narrowly defined in trials and the goal of them is the evaluation of activity and toxicity, and ultimately, the demonstration of a survival benefit. In practice, treate...
3 CitationsSource